NASDAQ:ADGM

Adagio Medical Q3 2025 Earnings Results & Report

Adagio Medical logo
$1.75 +0.09 (+5.42%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.75 +0.00 (+0.11%)
As of 11/20/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adagio Medical reported Q3 2025 earnings on October 30, 2025. The company reported EPS of -$19.80.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens

Adagio Medical EPS Results

Actual EPS
-$19.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Adagio Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adagio Medical Q3 2025 Earnings FAQ

Adagio Medical (NASDAQ:ADGM) reported earnings of -$19.80 per share for Q3 2025. The report was announced on Thursday, October 30, 2025.

Adagio Medical Earnings Headlines

Adagio Medical Reports Third Quarter 2026 Results
Seven bucks, yours for life: my Black Friday indicator deal
Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.tc pixel
Adagio Medical (ADGM) Expected to Post Earnings on Wednesday
ADGM - Adagio Medical Holdings, Inc.
See More Adagio Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email.

About Adagio Medical

Adagio Medical (NASDAQ:ADGM) is a medical technology company developing catheter-based systems for treating cardiac arrhythmias. Its technology uses ultra-low-temperature cryoablation, which applies very cold temperatures to create lesions in heart tissue that can interrupt abnormal electrical signals.

The company’s platform includes the vCLAS system, designed for ventricular arrhythmias such as ventricular tachycardia, and the iCLAS system, designed for atrial fibrillation. These systems are intended for use in catheter ablation procedures by cardiac electrophysiology teams.

View Adagio Medical Profile